Going after the phenomenon of 'regRNA,' Rick Young's Camp4 secures a launch round to push two programs forward
You’ve heard of mRNA, largely thanks to the Covid-19 vaccines developed by Pfizer/BioNTech and Moderna. If you watch the R&D space closely, you’ve also probably heard of oRNA and eRNA.
Now, a new biotech out of Rick Young’s Whitehead Institute lab at MIT wants to introduce you to regulatory RNA, or regRNA.
The company is Camp4 Therapeutics, and it’s locked down its first fundraise with a $45 million Series A on Tuesday. Led by CEO Josh Mandel-Brehm, Camp4 wants to create oligonucleotide-based medicines that control protein expression to help regulate any kind of genetic disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
